DNA and Histone Methylation in Prostate Cancer

Xu, Kexin

doi:10.1007/978-3-319-59786-7_18

Cited by 2 publications

(1 citation statement)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lysine and arginine are methylated on histones, mostly H3 and H4, by the two enzymes lysine methyltransferase (KMTs) and arginine methyltransferase (PRMTs) (Table 2) [29]. Various studies reported the clinical significance of aberrations related to methyltransferases and their association with different cancers [30][31][32]. A study reported that the KMT G9a is abnormally expressed in some brain tumors [33].…”

Section: Histone Methylation In Gliomamentioning

confidence: 99%

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

Azab

2023

JMP

View full text Add to dashboard Cite

Glioblastoma (GBM) is considered the most aggressive primary brain tumor. Recurrence after treatment is a significant problem with a failed response to optimal therapies. The recurrence of GBM is linked to different cellular and molecular pathways. Not only genetics are involved in gliomagenesis, but also epigenetics. Histone modulation through acetylation, phosphorylation, ubiquitination, and methylation can regulate gene expression and may play a role in the pathogenesis of GBM. Preclinical and clinical studies currently target epigenetic enzymes in gliomas, including a new generation of histone deacetylase (HDAC) inhibitors. Herein, I tried to highlight current research in glioma epigenetics, focusing on the culprit of histone modifications and the use of HDAC target therapies as a possible treatment line for glioblastoma.

show abstract

Section: Histone Methylation In Gliomamentioning

confidence: 99%

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

Azab

2023

JMP

View full text Add to dashboard Cite

show abstract

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article.

Azab¹

2023

Preprint

View full text Add to dashboard Cite

Glioblastoma is considered the most aggressive primary brain tumor. Recurrence after treatment is a significant problem with a failed response to optimal therapies. The recurrence of GBM is linked to different cellular pathways and molecular pathways. Not only genetics are involved in gliomagenesis, but also epigenetics. Epigenetic mechanisms are highly involved in the pathogenesis of GBM. Histone modulation through acetylation, phosphorylation, ubiquitination, and methylation can regulate gene expression and may play a role in the pathogenesis of GBM. Preclinical and clinical studies currently target epigenetic enzymes in gliomas, including a new generation of histone deacetylase (HDAC) inhibitors. Herein, I tried to highlight the current research in glioma epigenetics, focusing on the culprit of histone modifications and the use of HDAC target therapies as a possible treatment line for glioblastoma.

show abstract

DNA and Histone Methylation in Prostate Cancer

Cited by 2 publications

References 183 publications

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article.

Contact Info

Product

Resources

About